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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare the effectiveness and safety of adding focal laser therapy to systemically-delivered chemotherapy in treating intraocular
retinoblastoma.
B A C K G R O U N D
Description of the condition
Retinoblastoma is the most common intraocular malignancy of
childhood, with a constant incidence worldwide of 1:15,000 to
1:20,000 livebirths (Kivela 2009). In most cases the tumour is
initiated by a mutation in the RB1 gene, a tumour suppressor gene
located on chromosome 13q14, and mutations in both RB1 alleles
are a prerequisite for developing the cancer (Knudson 1971). In
heritable retinoblastoma, in which in most cases both eyes are
clinically affected, mutation in one RB1 allele is constitutional,
whereas a somatic mutation in the second allele initiates tumour
growth in the sensory retinal cells. In non-heritable RB1-related
retinoblastoma, both mutations are somatic, which gives rise to
unilateral disease in most cases. Retinoblastoma patients with the
heritable form are also prone to developing additional non-ocular
tumours (Eng 1993), and are at higher risk of developing trilateral
retinoblastoma, i.e. ocular retinoblastoma in conjunction with an
intracranial midline primitive neuroectodermal tumour (de Jong
2015).
The median age of diagnosis of unilateral retinoblastoma is 24
months and of bilateral retinoblastoma is 10 months (MacCarthy
2009). A white pupillary reflex, also termed leukocoria, is themost
commonpresenting clinical sign in both developing anddeveloped
countries (Abramson 1998; Bowman 2008; Menon 2009). Addi-
tional signs are strabismus, usually when the macula is involved,
and less frequently red eye, inflammation and additional non-spe-
cific signs (Abramson 1998). Early detection and urgent referral
to specialised retinoblastoma centres is of utmost importance in
order to salvage life, eye and vision. If untreated, retinoblastoma
will spread outside the globe, via the central nervous system, and
haematogenously, inevitably leading to death. In developing coun-
tries, in which there is a lack of educational strategies and infras-
tructure is poor, retinoblastoma patients’ survival rate is estimated
to be 40% or less (Dimaras 2012; Kivela 2009). In developed
countries, while these were the survival rates in early 20th century,
currently the five-year survival is estimated to be over 95% (Shields
2004).
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Treatment strategies for retinoblastoma have evolved significantly
throughout the years. Traditionally, retinoblastoma was treated by
removal of the eyeball (i.e. enucleation), a definite cure when the
tumour is contained within the globe. In advanced cases with ex-
traocular tumour extension, enucleation alone is not curative, and
further treatment is warranted. Currently, enucleation is reserved
only for advanced stage intraocular disease or as salvage treatment
after failure of other conservative modalities.
In seeking a treatment modality with better outcomes and less
morbidity, external beam radiotherapy (EBRT) was found to be an
effective alternative, and by the mid-20th century had largely re-
placed enucleation as the mainstay treatment for most retinoblas-
toma cases (Reese 1949; Stallard 1952). In order to better pre-
dict outcomes of retinoblastoma patients treated with EBRT, the
Reese-Ellsworth (R-E) classification for intraocular retinoblastoma
was developed (Reese 1964). It soon became an essential tool in its
management, and also enabled comparison of study results from
different centres. Unfortunately, after nearly half a century of ex-
tensive use of EBRT for retinoblastoma, it was recognised that
radiation significantly increases the risk to developing a secondary
cancer in survivors of hereditary retinoblastoma (Fletcher 2004;
Kleinerman 2005). As a result, radiotherapy was widely aban-
doned and replaced by chemotherapy as the primary treatment
for intraocular retinoblastoma. To date, it is reserved only as a last
resort when all other modalities have failed.
Description of the intervention
Systemically administered chemotherapy for retinoblastoma is
used as adjuvant treatment when high-risk histopathological fea-
tures are found after enucleation, to treat systemic retinoblastoma
spread and as primary treatment for intraocular disease. Kupfer
1953 described the first use of chemotherapy for the latter indica-
tion and attempts to combine EBRT and chemotherapywere soon
published (Reese 1958). However, it was abandoned and formany
years reserved only for extraocular disease. The use of systemic che-
motherapy as a primary treatment modality for intraocular disease
was revived in the 1990s in London using potent chemotherapeu-
tic agents, namely vincristine, etoposide and carboplatin (VEC).
The VEC regimen was first given in combination with EBRT and
resulted in 70% of eyes salvaged (Kingston 1996). In subsequent
studies, systemic chemotherapy with additional focal therapy was
used as an alternative to EBRT and resulted with high eye salvage
rate (Gallie 1996;Murphree 1996; Shields 1996). Soon after it was
first introduced, the VEC regimen became the standard protocol,
given through a central venous access line every three weeks for six
cycles. In order to better predict the outcomes of retinoblastoma
patients treated with chemotherapy, a new classification scheme,
the International Classification of Retinoblastoma (ICRB), was
introduced in early 2000s to replace the R-E classification, which
became less relevant (Murphree 2005). One of the main features
integrated into the ICRB scheme was the presence of retinoblas-
toma seeds (vitreal or subretinal, or both), as it was recognised
that seeding is a predictor for failure after chemotherapy. Despite
some discrepancies in its interpretation, the ICRB is currently
used throughout the world (Novetsky 2009). Early use of sys-
temic chemotherapy in conjunctionwith radiationwas reported to
cause serious side effects and therefore abandoned (Reese 1958). In
the VEC regimen era, possible chemotherapy-related side effects
include febrile episodes, temporary alopecia, bone marrow sup-
pression, peripheral neuropathy and allergic reactions to the sub-
stances used, but the incidences of which are poorly documented.
Carboplatin was suggested to cause ototoxicity (Lambert 2008),
and etoposide to induce secondary acute myelogenous leukaemia
(Gombos 2007; Turaka 2012); both on rare occasions. In an at-
tempt to avoid potential systemic complications of systemically-
delivered chemotherapy, newmethods of delivery were developed,
namely intra-arterial and intravitreal chemotherapy. The former
method of delivery was developed in Japan (Yamane 2004), and
was refined in theUSA (Abramson2008). The latterwas developed
in Sweden (Ericson 1961; Seregard 1995), and is extensively used
in Japan and Switzerland (Kaneko 2003; Munier 2012). There is
increasing enthusiasm towards the use of these selectivemodalities,
and in some centres they have replaced systemic chemotherapy
as a primary treatment for intraocular retinoblastoma (Abramson
2015). Despite these trends, the indications for use and whole
spectrum of side effects and complications are not yet fully under-
stood. Worldwide, systemically-delivered chemotherapy remains
a major therapeutic option for unilateral and especially bilateral
retinoblastoma.
Focal laser is the treatment of choice for small postequatorial
tumours. It is also used in combination or after administration
of chemotherapy for larger tumours and for tumour recurrence
(retinal or subretinal) after successful initial treatment by various
modalities. Though it was initially performed by means of light
photocoagulation, currently most centres use an 810 nm mod-
ified diode laser, termed transpupillary thermotherapy (TTT).
Lagendijk 1982 performed the first description of TTT as treat-
ment for intraocular retinoblastoma, which used a microwave ap-
plicator and successfully treated two patients with recurrent dis-
ease. It has since been used successfully as a primary sole treatment
for ICRB group A eyes, and has resulted in a high rate of tumour
control. Shields 1999 used TTT to primarily treat 188 tumours in
a mean base diameter of 3mm and elevation of 2mm, and showed
that a complete regression was achieved in 86% of the tumours.
In a case series of 91 tumours that measured less than 1.5 disc di-
ameters (DD), Abramson 2004a showed that 92% of the tumours
were cured with TTT alone. The procedure is performed using
indirect ophthalmoscopy through dilated pupils, with the laser
beam exiting the head piece and aimed at the intraocular tumour.
The laser is applied for a prolonged period of time (minimum nine
seconds per application) as compared to laser photocoagulation.
The number of applications, spot size, power energy and treat-
ment end points vary between different centres (Abramson 2004a;
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Brichard 2002; Levy 1998; Lumbroso 2002; Shields 2002).
How the intervention might work
Systemic chemotherapy
Historically, chemotherapy was considered to be ineffective for
intraocular retinoblastoma, and therefore was not used for this
indication (White 1983). However, several advances in the field
of chemotherapy for paediatric cancers have driven physicians
and scientists to revisit this paradigm: carboplatin, a cisplatin
analogue with an improved side effect profile, was found to be
an effective chemotherapeutic agent for other neuroectodermal
solid tumours (i.e. neuroblastoma) (Gaynon 1994), was shown to
cross the blood-brain barrier (Riccardi 1992), and together with
etoposide was found to be effective for extraocular retinoblas-
toma (Doz 1995). Kingston and colleagues’ above-mentioned pi-
lot study using VEC in conjunction to EBRT, salvaging most R-
E group V eyes (Kingston 1996), paved the way for additional
clinical trials and also empirical experimental studies. Murphree
and colleagues measured carboplatin concentrations in enucleated
retinoblastoma eyes after systemic administration of the agent and
found it was at significant levels (Murphree 1996). In addition,
carboplatinwas found to effectively inhibit tumour growth in both
in vivo and in vitro experimental models (Harbour 1996; Murray
1997).
Systemic chemotherapy and focal laser treatment
While some use chemotherapy as the sole primary treatment for
intraocular retinoblastoma (Gombos 2002), others claim it to be
insufficient to combat the disease; they have stated that it merely
reduces tumour size, thus enabling further focal therapies to be
applied to achieve full tumour control (Murphree 1996; Shields
1996; Shields 2005). The use of chemotherapy in this manner,
termed chemoreduction, has roots in treatments of other solid tu-
mours (Dropcho 1992; Follézou 1989; Larner 1995). In a study by
Shields and colleagues, chemotherapy for intraocular retinoblas-
toma resulted in complete tumour response in 46% of the patients
and a partial response that warranted additional focal treatments
in the remaining patients (Shields 1996). None of the patients
required enucleation, although EBRT was necessary in 29% of
eyes because of diffuse vitreous seeds. Wilson 2001 treated 20
retinoblastoma patients with eight cycles of vincristine and carbo-
platin, and found that in 92% of cases tumours progressed after
chemotherapy and required adjuvant supplemental focal thera-
pies. Shields 2005 performed a prospective non-randomised study
in which 28 of 68 tumours were treated by means of systemic che-
motherapy alone and 40 of 68 were treated with chemotherapy
combined with foveal-sparing TTT. The study findings indicated
that recurrence in the group that received chemotherapy alone
occurred in 35% of tumours at four years follow-up versus 17%
in the combined treatment group. In support of the combined
use of TTT and chemotherapy, not only the insufficient role of
chemotherapy alone is stated but also the beneficial interaction
of heat energy and chemotherapy. The use of thermal energy in
conjunction with chemotherapy has been shown to be synergis-
tic (Da Silva 1987; Herman 1994), and to enhance the cytotoxic
effect of carboplatin in vivo (Tapazoglou 1991). In addition, in
a transgenic murine retinoblastoma cell line, the cytocidal inter-
action of heat and carboplatin were found to be superior to each
of the monotherapies (Murray 1997). Lumbroso 2002 treated 51
children (103 tumours) with TTT that was administered shortly
after injection of carboplatin.Over 96%of tumours regressed after
a median follow-up time of 30 months. The use of systemic che-
motherapy alone for intraocular retinoblastoma was advocated as
focal laser therapy was found to cause large scotomas (Abramson
2004b). The laser scar may also increase in size (Lee 2004). Also,
rates of vitreous or vitreous base relapse are thought to increase
with a longer duration of TTT (Gombos 2006). Schefler and col-
leagues assessed patients treated with chemotherapy and repetitive
TTT ablations (Schefler 2007). Nearly 90% of eyes achieved con-
trol at three years follow-up. However, over 60% of children de-
veloped iris atrophy with laser treatment. Gombos and colleagues
retrospectively reviewed retinoblastoma patients treated with pri-
mary systemic chemotherapy alone and found that in 72% of cases
there was no need for additional treatment (Gombos 2002).
Why it is important to do this review
To date there has been no systematic review of randomised trials
to summarise the evidence of the effectiveness and safety of focal
laser therapy in retinoblastoma patients treated with systemic che-
motherapy. Also, there is no consensus as to the preferred timing
of laser therapy application, if used, after chemotherapy admin-
istration. While in some practices focal laser treatment is added
only if required, in others it is used at a prefixed timing in regard
to the chemotherapy courses given (i.e. before or after a specific
predetermined chemotherapy course). In addition, there is clinical
uncertainty as for which group classification (R-E or ICRB) focal
laser treatment is best used as an adjunct to systemic chemother-
apy.
As retinoblastoma is a sight- and life-threatening disease, it is im-
portant to establish the preferred practice in terms of efficacy and
safety of focal laser therapy added to systemically-delivered che-
motherapy.
O B J E C T I V E S
To compare the effectiveness and safety of adding focal laser ther-
apy to systemically-delivered chemotherapy in treating intraocular
retinoblastoma.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will only include randomised controlled trials (RCTs).
Types of participants
Participants diagnosed with intraocular postequatorial retinoblas-
toma in either one or both eyes. There will be no restrictions re-
garding age, gender, ethnicity, co-morbidities of participants or
the number of trial participants.
Types of interventions
We will include trials that compare chemotherapy plus laser treat-
ment versus chemotherapy alone. There will be no restrictions on
the type of laser used (i.e. laser beam wavelength).
Types of outcome measures
Primary outcomes
The proportion of eyes with recurrence of tumours within three
years from treatment.
Secondary outcomes
• The proportion of eyes that require external beam
radiotherapy (EBRT) or enucleation at any time point.
• The proportion of enucleated eyes at any time point with
high risk histopathological characteristics for tumour progression
and metastasis (i.e. invasion of the postlaminar optic nerve,
choroid, sclera and anterior chamber) (Khelfaoui 1996).
• The proportion of enucleated eyes with extraocular tumour
spread at any time point.
• Metastatic spread: the proportion of participants with
distant metastatic spread at any time point.
• Survival: the proportion of participants that died due to
metastatic spread at any time point.
• Total number of additional treatments given.
• Time from last treatment (i.e. chemotherapy or laser
treatment) to tumour relapse.
• Visual acuity of 6/60 or better versus worse than 6/60
measured at least 12 months after initial treatment.
Adverse outcomes
We will compare complications and adverse events between treat-
ment groups that occur throughout follow-up for all included tri-
als. Complications will include those from chemotherapy or use
of laser therapy, or both. Adverse effects of interest will include
but will not be limited to the following.
• Retinal scar.
• Retinal tear.
• Development of vitreous seeds.
• Iris atrophy.
• Neovascularisation at the disc, retina elsewhere, iris or
anterior chamber angle.
• Chorio-retinal ischaemia.
• Systemic adverse effects of any kind.
• Death.
Follow-up
We will not place any restrictions on the duration of follow-up.
Search methods for identification of studies
Electronic searches
We will search CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (latest issue), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
present), Embase (January 1980 to present), Latin American
and Caribbean Health Sciences Literature Database (LILACS)
(1982 to present), the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/
en). We will not use any date or language restrictions in the elec-
tronic search for trials.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), Embase (Appendix 3),
LILACS (Appendix 4), ISRCTN (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the WHO ICTRP (Appendix 7).
Searching other resources
We will search the citation lists of reports from trials we identify
from the literature search to look for additional trials. We will not
conduct manual searches of conference proceedings or abstracts
specifically for this review.
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Data collection and analysis
Selection of studies
Two review authors will independently screen the titles and ab-
stracts that result from the searches by using internet-based soft-
ware (Covidence 2015). They will classify each record as either
’definitely relevant’, ’possibly relevant’ or ’irrelevant’. They will
obtain full-text copies of records classified as ’definitely relevant’
or ’possibly relevant’ after discussion between the review authors.
They will classify each full-text report as either ’included’, ’await-
ing assessment’ or ’excluded’. A third review author will resolve any
disagreements regarding full-text assessments. For studies written
in languages not understood by the review authors, we will use
Google Translate or we will request translation of the full-text re-
port in order to determine eligibility. We will contact the primary
study investigators to clarify the eligibility of studies classified as
’awaiting assessment’. We will document the reasons for excluding
studies identified by both review authors as ’excluded’. Also, we
will list the excluded studies and their reasons for exclusion in a
’Characteristics of excluded studies’ table. The review authors will
not be masked to the report authors, institutions and trial results
during these assessments. We will create a PRISMA diagram to
illustrate the study selection process.
Data extraction and management
Two review authors will independently extract data using a
prepiloted online form and the web-based software Covidence
(Covidence 2015). One review author will enter data into Review
Manager (RevMan) (RevMan 2014), and the second review au-
thor will review the accuracy of the work performed by the first
review author.
Assessment of risk of bias in included studies
Two review authors will assess the risk of bias in the included stud-
ies using the Cochrane ’Risk of bias’ assessment tool as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). This assessment will include assess-
ing sequence generation, allocation concealment, completeness of
data, selective outcome reporting and other potential sources of
bias. We will construct a ’Risk of bias’ table, in which we will iden-
tify whether any of these types of bias are present in each included
study, the risk that the bias compromised the results of the study
and supporting evidence for these judgments. Two review authors
will conduct these assessments and will resolve any disagreements
by consensus or arbitration by a third review author.
Measures of treatment effect
We will present dichotomous data as risk ratios with 95% confi-
dence intervals (CIs).
• Primary outcome: proportion of eyes with recurrence of
tumours within three years from treatment.
• Secondary outcome: proportion of eyes (enucleated or
treated with EBRT, eyes with high risk histopathological features
and eyes with extraocular tumour spread), proportion of
participants (distant metastatic spread and death), visual acuity
(better versus worse than 6/60).
• Adverse outcomes.
We will present continuous data as mean differences with 95%
CIs.
• Secondary outcome: number of additional treatments,
visual acuity and visual field when assessed as means or mean
deviation.
Unit of analysis issues
In our analyses, we will compare eyes treated with chemotherapy
and additional laser therapy versus those treated with chemother-
apy alone. Trials may randomise tumours, eyes or participants to
the intervention or comparator. We will record details of study
design with respect to treatment modality (chemotherapy with/
without laser therapy), treatment of one or more tumours, one or
both eyes of the participant. If a study randomly allocates partic-
ipants to treatment but includes and reports all tumours or both
eyes, we will analyse the data as ’clustered data’, i.e. we will adjust
for within-person correlation. If insufficient information is avail-
able in the article, we will attempt to contact the study authors for
clarification.
Dealing with missing data
We anticipate thatmissing data will be present within the included
studies. We will analyse studies using an available-case analysis.
We will record the percentage of missing data from each inter-
vention group in all included studies, and examine the reasons, to
determine whether it meets the assumption of data being missing
at random. We will consider studies that exhibit an unequal rate
(greater than 20%) of missing data between intervention groups
as at risk of attrition bias.
Assessment of heterogeneity
We will assess heterogeneity and inconsistency among trials sta-
tistically using the I² statistic value to assess if variability in effect
is due to sampling error. We will also assess diversity between the
included studies by reviewing participant characteristics and trial
methodology.
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Assessment of reporting biases
We will assess selective outcome reporting when we judge individ-
ual studies for risk of bias. We will assess reporting biases by ex-
amining funnel plots when we include 10 or more RCTs in meta-
analyses.
Data synthesis
When we do not detect any substantial clinical or methodological
heterogeneity, we will combine the results in a meta-analysis. If
there are three or fewer eligible RCTs, thenwewill use a fixed-effect
model for the meta-analysis. If more than three trials meet the
inclusion criteria, wewill use a random-effectsmodel. If substantial
heterogeneity is present and the direction of effect is inconsistent
across the included studies, we will not combine the data in a
meta-analysis but we will present a descriptive summary.
Subgroup analysis and investigation of heterogeneity
We will attempt to perform a subgroup analysis according to tu-
mour grouping (i.e. Reese-Elsworth Classification I-V (R-E I-V)
and International Classification of Retinoblastoma groups A-E
(ICRB A-E)).
Sensitivity analysis
We will conduct one sensitivity analysis, and will exclude studies
that are at high risk of bias in one or more domain.
’Summary of findings’ table
Two review authors will independently assess the overall quality
of the evidence for each outcome using the GRADE classification
(GRADEpro 2014). We will include the following outcomes in
the ’Summary of findings’ table.
• The proportion of eyes with recurrence of tumours within
three years from treatment.
• The proportion of eyes that require EBRT or enucleation at
any time point.
• The proportion of enucleated eyes at any time point with
high risk histopathological characteristics for tumour progression
and metastasis.
• The proportion of enucleated eyes with extraocular tumour
spread at any time point.
• The proportion of participants with distant metastatic
spread at any time point.
• The proportion of participants that died due to metastatic
spread at any time point.
• Adverse outcomes.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Retinal Neoplasms] explode all trees
#2 retinoblastoma*
#3 retina* near/3 (cancer* or neoplas* or tumor* or tumour* or malignan* or carcinoma* or adenocarcinoma* or sarcoma*)
#4 MeSH descriptor: [Eye Enucleation] explode all trees
#5 enucleat* or envicerat*
#6 (eye* or globe) near/2 (remov* or extract*)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Antineoplastic Agents] explode all trees
#9 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#10 MeSH descriptor: [Combined Modality Therapy] explode all trees
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#11 chemotherap* or chemoreduct* or chemothermotherap* or chemoprophyla*
#12 MeSH descriptor: [Vincristine] this term only
#13 MeSH descriptor: [Etoposide] this term only
#14 MeSH descriptor: [Carboplatin] this term only
#15 vincristine* or etoposide* or carboplatin*
#16 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Lasers] explode all trees
#18 MeSH descriptor: [Light Coagulation] this term only
#19 laser*
#20 photocoagulat*
#21 transpupillary near/2 thermotherap*
#22 TTT
#23 #17 or #18 or #19 or #20 or #21 or #22
#24 #7 and #16 and #23
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp Retinal Neoplasms/
14. retinoblastoma$.tw.
15. (retina$ adj3 (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or carcinoma$ or adenocarcinoma$ or sarcoma$)).tw.
16. Eye Enucleation/
17. (enucleat$ or envicerat$).tw.
18. ((eye$ or globe) adj2 (remov$ or extract$)).tw.
19. or/13-18
20. exp Antineoplastic Agents/
21. Antineoplastic Combined Chemotherapy Protocols/
22. exp Combined Modality Therapy/
23. (chemotherap$ or chemoreduct$ or chemothermotherap$ or chemoprophyla$).tw.
24. Vincristine/
25. Etoposide/
26. Carboplatin/
27. (vincristine$ or etoposide$ or carboplatin$).tw.
28. or/20-27
29. exp Lasers/
30. Light Coagulation/
31. laser$.tw.
32. photocoagulat$.tw.
33. (transpupillary adj2 thermotherap$).tw.
34. TTT.tw.
35. or/29-34
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36. 12 and 19 and 28 and 35
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville Glanville 2006.
Appendix 3. Embase (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp eye tumor/
34. retinoblastoma$.tw.
35. (retina$ adj3 (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or carcinoma$ or adenocarcinoma$ or sarcoma$)).tw.
36. Enucleation/
37. (enucleat$ or envicerat$).tw.
38. ((eye$ or globe) adj2 (remov$ or extract$)).tw.
39. or/33-38
40. exp chemotherapy/
41. antineoplastic agent/
42. multimodality cancer therapy/
43. chemoprophylaxis/
44. (chemotherap$ or chemoreduct$ or chemothermotherap$ or chemoprophyla$).tw.
45. vincristine/
46. etoposide/
47. carboplatin/
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48. (vincristine$ or etoposide$ or carboplatin$).tw.
49. or/40-48
50. exp laser/
51. exp laser coagulation/
52. laser$.tw.
53. photocoagulat$.tw.
54. (transpupillary adj2 thermotherap$).tw.
55. TTT.tw.
56. or/50-55
57. 39 and 49 and 56
58. 32 and 57
Appendix 4. LILACS search strategy
retinoblastoma or enucleat$ or evicerat$ or retinal cancer$ or retinal neoplasm$ or retinal tumor$ or retinal tumour$ or retinal
malignan$ or retinal carcinoma$ or retinal adenocarcinoma$ or retinal sarcoma and chemotherapy or antineoplastic or chemoreduction
or chemothermotherapy or chemoprophylaxis or vincristine or etoposide or carboplatin and laser$ or photocoagulat$ or coagulat$ or
thermotherap$
Appendix 5. ISRCTN search strategy
(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR
retinal malignant OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) AND (chemotherapy OR antineoplastic OR
chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin)
Appendix 6. ClinicalTrials.gov search strategy
(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR
retinal malignant OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) AND (chemotherapy OR antineoplastic OR
chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin)
Appendix 7. WHO ICTRP search strategy
(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR
retinal malignan OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) = CONDITION AND (chemotherapy OR
antineoplastic OR chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin)
= INTERVENTION
Appendix 8. Data on study characteristics
Mandatory items Optional items
Methods
Study design • Parallel group RCT i.e. people
randomised to treatment.
Exclusions after randomisation
Losses to follow-up
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(Continued)
• Within-person RCT i.e. eyes
randomised to treatment.
• Cluster RCT i.e. communities
randomised to treatment.
• Cross-over RCT.
• Other, specify.
Number randomised/analysed
How were missing data handled? e.g. avail-
able-case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or unit of randomisation/unit of anal-
ysis
• One eye included in the study;
specify how the eye was selected.
• Two eyes included in the study, both
eyes received same treatment; briefly
specify how analysed (best/worst/average/
both and adjusted for within person
correlation/both and not adjusted for
within person correlation) and specify if a
mixture of 1 eye and 2 eyes.
• Two eyes included in study, eyes
received different treatments, specify if
correct pair-matched analysis was done.
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for
total study population recruited into the
study. If the study only reports these data
for the participants who were followed up
only, please indicate
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (N = )
Comparator (N = )
(See MECIR 65 and 70)
• Number of people randomised to
this group.
• Drug (or intervention) name.
• Dose.
• Frequency.
• Route of administration.
Outcomes
Primary and secondary outcomes as de-
fined in study reports
(See MECIR R70)
List outcomes
Adverse events reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
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(Continued)
Notes
Date conducted Specify dates of recruitment of participants
month/year (mm/yr) to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declarations of interest
(See MECIR 69)
Abbreviations
MECIR: Methodological Expectations of Cochrane Intervention Reviews; RCT: randomised controlled trial
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